Federal Trade Commission v. AbbVie Inc, et al

  1. January 15, 2020

    FTC Tells 3rd Circ. AbbVie Pay-For-Delay Case Axed Too Early

    The Federal Trade Commission urged the Third Circuit to revive the agency's antitrust claim that AbbVie paid off Teva Pharmaceuticals to delay Teva's generic version of the testosterone treatment AndroGel, saying at oral argument Wednesday that a lower court tossed the suit before the FTC had a chance to back it up.

  2. October 29, 2019

    ​​​​​​​Allergan's $750M Deal Among Pharma's Top Antitrust Payouts

    A $750 million settlement this week by Allergan to avert an antitrust trial involving Alzheimer's drug Namenda is among the most eye-popping sums ever shelled out by a drugmaker for allegedly thwarting generic competition.

  3. July 26, 2019

    AARP Backs Up FTC At 3rd Circ. In AbbVie Antitrust Suit

    AARP called on the Third Circuit Friday to knock down the argument from AbbVie Inc. and an affiliate that a district court was not permitted to hit them with a $448 million penalty in an antitrust suit from the Federal Trade Commission over AbbVie's AndroGel testosterone replacement drug.

  4. July 22, 2019

    FTC Asks 3rd Circ. To Revive Claims In AbbVie Antitrust Case

    The Federal Trade Commission has urged the Third Circuit to revive pay-for-delay claims in the agency's antitrust suit against AbbVie Inc. and an affiliate, calling the lower court's decision to nix the claims "a fundamental error that reverberated throughout this case."

  5. June 13, 2019

    Chamber, Drugmakers Back AbbVie In $448M FTC Fine Appeal

    Drugmakers and the U.S. Chamber of Commerce have urged the Third Circuit to overturn a ruling that slammed AndroGel maker AbbVie with $448 million in penalties for bringing “sham” patent suits to slow down generic competitors, arguing that the Pennsylvania federal judge on the case made it harder to file legitimate patent defenses.

  6. March 29, 2019

    $448M Win In AbbVie Case Not Enough, FTC Tells 3rd Circ.

    The Federal Trade Commission has urged the Third Circuit to revive parts of an antitrust action against AbbVie Inc. and an affiliate, even after winning a $448 million penalty against the drugmakers, saying their illegal profits from alleged sham patent litigation were nearly triple that amount.